Wave Life Sciences (WVE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 5. Analyst Joseph Schwartz from Leerink Partners maintained a Buy rating on the stock and has a $24.00 price target.
Joseph Schwartz has given his Buy rating due to a combination of factors including the promising developments in Wave Life Sciences’ pipeline. The company has shown significant progress in its obesity program with the rapid enrollment in the Phase 1 INLIGHT study for WVE-007, which is expected to yield data updates in the latter half of 2025. This study focuses on both total weight loss and body composition, indicating a comprehensive approach to addressing obesity.
Furthermore, Wave Life Sciences is advancing its Duchenne muscular dystrophy (DMD) program, with additional 48-week data for WVE-N531 anticipated by the end of the quarter, building on the positive 24-week data from the previous year. The company is also preparing for multiple clinical trial applications for its Huntington’s disease (HD) program, with a potentially registrational study planned for the second half of 2025. These strategic advancements, along with the potential regulatory updates, support the optimistic outlook and the Buy rating for Wave Life Sciences.
In another report released on March 5, H.C. Wainwright also maintained a Buy rating on the stock with a $22.00 price target.
WVE’s price has also changed dramatically for the past six months – from $5.230 to $10.570, which is a 102.10% increase.